GNFT - Genfit S.A.
3.6695
0.030 0.804%
Share volume: 10,513
Last Updated: 04-28-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.12%
PREVIOUS CLOSE
CHG
CHG%
$3.64
0.03
0.01%
Fundamental analysis
0%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
0%
Performance
5 Days
-0.01%
1 Month
7.30%
3 Months
4.25%
6 Months
4.25%
1 Year
4.25%
2 Year
4.25%
Key data
Stock price
$3.67
DAY RANGE
$3.63 - $3.87
52 WEEK RANGE
$2.55 - $3.87
52 WEEK CHANGE
$4.25
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-24-2025
Company detail
CEO: Pascal Prigent
Region: US
Website: genfit.com
Employees: 120
IPO year: 2019
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: genfit.com
Employees: 120
IPO year: 2019
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Genfit S.A. discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. Elafibranor is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test.
Recent news
